One of the available Hybrid closed loop system is MiniMed 670G (Medtronic Diabetes, Northridge, CA, USA), which is indicated for children above 7 years old, adolescents and adults with Type 1 Diabetes. Several studies have shown improved HbA1c, time in target range, and SG variability in children, adolescents and adults with Type 1 Diabetes, where participants were experienced with using CSII therapy, assuming that the success of HCL systems depend on prior use of pump therapy. A recent study, published by diabetes team from Sidra Medicine, Doha has showed that children and adolescents with Type 1 Diabetes on MDI therapy can successfully initiate the HCL system, using a concise structured 10-day protocol, achieving better outcomes than in previous studies, where participants had previous experience with diabetes related technology and longer initiation process.

The AHCL system, Minimed 780G is CE-marked includes additional functionality aiming to provide further protections from highs. The user can choose the algorithm to target a glucose level of 100 or 120 mg/dL. Like for the MiniMed 670G HCL system, users can also choose the algorithm to temporarily target a glucose value of 150 mg/dL. In addition, the AHCL system has the ability to administer correction bolus automatically, targeting 120 mg/dL. The AHCL algorithm was evaluated with a model-based algorithm design platform incorporating a virtual patient simulator, where additional changes were made (lower target ranges and automated correction boluses ( )). A recent study including 12 patients with type 1 diabetes on AHCL system, has shown no episodes of hypoglycemia or diabetic ketoacidosis, while maintaining 99% time spent in closed loop and high time in ra1]\nge ( ). AHCL decreased Auto Mode exits and alerts, and improves glycaemia without compromising safety, despite multiple food and exercise challenges ( ).

Sidra Medicine is the only center for childhood diabetes in Qatar. Around 80% of type 1 diabetes patients are using a device (insulin pump/glucose sensor) and around 45% are using sensor-augmented pump (SAP)/HCL systems.

This study is a single-arm, single-center, clinical investigation in subjects with type 1 diabetes on AHCL insulin pump in a period of 3 months.

The study will include an 9-month extension phase, to which participants may voluntarily decide to take part in, cumulating a total of one-year period duration. Visits wil be scheduled every 3 months, as per routine practice. TIR, HbA1c, demographics and clinical data will be analyzed on 3 months period.

A total of 33 subjects (age 7-17 years) will be enrolled in order to reach 30 subjects who will complete the 3 months study.

After reviewing the patient's eligibility and interest, the investigators will obtain informed consent and assent as appropriate. The investigators will start the clinical process for initiating an insulin pump, which is typically done with pre-pump classes. A clinically obtained HbA1c assessment will be performed via fingerstick and DCA 2000 at baseline and 3 months during the study.

Collection of demographics and medical history, data for diabetes devices (eg meters, sensors, pumps) and brief clinical physical exam including vital signs and skin assessment will be obtained via Hospital Electronic Medical File (Cerner Millennium) and will be kept as electronic data on a separate research server.

The different continuous baseline values will be checked for normality of distribution using the mean-median comparison, skewness and kurtosis (-3 to +3), spread, Kolmogorov-Smirnow and Shapiro-Wild tests, outliers, histograms and Q-Q-plots.

The initiation protocol consisted of four main stages: AHCL system compatibility assessment, AHCL system training, Manual Mode and Auto Mode stages.

Step 1. AHCL system compatibility assessment

Step 1 will be used to select participants for the study, based on inclusion and exclusion criteria (explained below) as well as patients' interest. It consists of 2 sessions:

AHCL System Introduction session (Clinic visit), one-hour duration (groups of 8-12 patients), where the AHCL system will be explained. Individuals' responsibilities (e.g. bolusing before meal, calibrating the system 3-4 times per day, responding to alerts and alarms, downloading pump data from home) and expectations (e.g. improvements in glycemic control, less glucose variability, hypoglycemia minimization, workload of diabetes management) will be discussed.

AHCL System readiness session, 1-hour duration, where evaluation will be performed on carb counting, bolus for carbs and correction, SMBG. Participants will send food log diary and phone call consultation will be performed.

Step 2: AHCL system training

A similar approach currently used in Sidra for MiniMed 670G system initiation will be used in the study. AHCL system training will be performed in groups (three to five individuals and their parents/guardians). The program includes three sessions of two to three hours on three consecutive days. CGM will be initiated the first day of the training, for education and observational purposes and for baseline data collection (no insulin delivery by the pump) Details are explained in the table:

Each session will be provided by two educators from 12pm to 3pm. Timing of the long acting insulin injection will be moved two hours ahead each day during training sessions, to reach 12pm the day before the HCL system initiation in Manual Mode, to avoid the use of temporary basal at insulin pump initiation.

Step 3: Manual Mode Participants will initiate the use of the AHCL system in Manual Mode (Clinic visit) with suspend before low feature for 72 hours to allow the algorithm to collect insulin utilization and CGM data to establish personalized Auto Mode initiation parameters. Sidra's validated protocol for SAP initiation (Auto-Generator app), also used in 10-day initiation protocol, with review of CGM data (step 2) will be used: in short, the protocol inputs the current insulin program (MDI), calculates a 10 to 20% reduction of total daily dose, with a 40/60 basal/bolus distribution in four or five basal rates. Insulin to carbohydrate ratio (ICR) settings utilizes the formula of 300-450/Total Daily dose (TDD) and, the formula of 90-110/TDD (mmol/l) with two CF settings, the nighttime CF factor is set 10-20% higher than the daytime CF. Active insulin is set time (3 hours), suspend before low feature is turned on with a threshold of 3.0-3.8 mmol/l (55-70 mg/dl) and glucose target range from 5.0 mmol/l to 7.2 mmol/l (90-130 mg/dl).

Step 4: Auto Mode The Auto Mode feature of the AHCL system will be activated 72 hours after manual mode initiation (virtual visit, using Skype Meet) and will be used continuously for 84 days.

The patient/family will upload data into the CareLink system, and the data will be reviewed by a member of the clinical team. Adjustments to system settings will be suggested to the family as clinically appropriate. The rationale for system setting adjustments will be documented.

Follow up visits will be performed on 7, 14, 28 days of aHCL initiation. After the first month of aHCL system, visits will be every three months during the study.

HbA1c will be obtained using point of care DCA Vantage Analyzer (Siemens, Erlangen, Germany) at baseline and at the end of the study.

The study will submit the proposal to Local and National Ethics Committee in Qatar to get Ethical approval before commencing the study.

Inclusion Criteria:

1. Clinical diagnosis of type 1 diabetes >1 year prior to consent date. Diagnosis of type 1 diabetes is based on the investigator's judgment; C peptide level and antibody determinations are not required.
2. HbA1c < 12.5%
3. Age 7-17 years at the initiation of the system
4. Multiple Daily Injections (Basal Bolus therapy) with Total daily insulin use of great than 8.0 units per day over a 1-week period
5. Willing and able (access to internet from home) to download information into the Medtronic CareLink software
6. Clinically able to start the AHCL system
7. History of 3 clinic visits in the last year

Exclusion Criteria:

1. DKA in the 6 months prior to screening visit
2. Pregnancy
3. Untreated diabetes retinopathy, or other causes that ,in the investigator's opinion, precludes the individual from participating in the trial.

Participants with Type 1 Diabetes, on multiple daily injections, using self-monitoring of blood glucose or continuous glucose monitoring, no prior pump experience.

It depends on Institution decision, waiting response